Form 4: NewAmsterdam Pharma Chief Legal Officer Acquires Significant Equity and Options

Michael F. Marino III, Chief Legal Officer and Corporate Secretary of NewAmsterdam Pharma Co N.V., has acquired 55,000 restricted stock units and 315,000 stock options, aligning his interests with long-term shareholder value.

Summary

• Michael F. Marino III, the Chief Legal Officer and Corporate Secretary of NewAmsterdam Pharma Co N.V. (NAMS), reported the acquisition of company securities.
• On June 1, 2025, Mr. Marino acquired 55,000 Ordinary Shares in the form of Restricted Stock Units (RSUs).
• These RSUs will vest in three equal annual installments (1/3 each) on the first, second, and third anniversaries of the June 1, 2025 vesting start date, contingent upon his continued service.
• Additionally, on June 1, 2025, Mr. Marino acquired 315,000 stock options with an exercise price of $18.11 per share.
• The stock options have an expiration date of June 1, 2035.
• The options' vesting schedule includes 25% on June 1, 2026 (the one-year anniversary of the vesting start date), with the remaining shares vesting in equal monthly installments over the subsequent three years, subject to continued service.

Sentiment

Score: 7

Explanation: The acquisition of significant equity and options by a key executive, coupled with long vesting periods, indicates strong alignment of management's interests with long-term shareholder value and confidence in the company's future. This is generally viewed positively by the market as it signals insider confidence and commitment.

Positives

• The acquisition of 55,000 Restricted Stock Units (RSUs) by a key officer demonstrates a direct alignment of management's interests with those of shareholders.
• The grant of 315,000 stock options to the Chief Legal Officer provides a significant long-term incentive for the executive to contribute to the company's growth and success.
• The multi-year vesting schedules for both RSUs (3 years) and options (4 years) encourage long-term retention and sustained performance from a senior executive.

Future Outlook

The acquisition of long-term equity incentives by a key executive suggests a positive internal outlook on the company's future performance and aligns the executive's interests with long-term shareholder value creation.

Management Comments

• Michael F. Marino III is identified as Chief Legal Officer and Corporate Secretary.
• The transactions were made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

In the biotechnology and pharmaceutical industry, attracting and retaining top talent, especially in legal and corporate governance roles, is crucial. Granting significant equity and options with long vesting periods is a common practice to incentivize executives and align their performance with the company's long-term success and drug development milestones.

Comparison to Industry Standards

• The grant of RSUs and stock options with multi-year vesting schedules is a standard practice in the pharmaceutical and biotechnology sectors for executive compensation, comparable to practices at companies like Moderna, BioNTech, or Pfizer, which use similar long-term incentive plans to retain key personnel and align their interests with shareholder value.
• The specific exercise price of $18.11 for options would typically be set at or above the market price on the grant date, a common approach to ensure that the options only become valuable if the company's stock price appreciates, incentivizing growth.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term shareholder value through equity compensation.
• Employees: May signal stability and confidence in leadership, potentially boosting morale.

Next Steps

• Continued service of Michael F. Marino III to ensure vesting of RSUs and options.
• Future vesting dates for RSUs on the first, second, and third anniversaries of June 1, 2025.
• Future vesting dates for options, with 25% on June 1, 2026, and remaining monthly over three years.

Key Dates

Recommendation

Keywords

NewAmsterdam Pharma, NAMS, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Chief Legal Officer, Corporate Secretary, Michael F. Marino III, Biotechnology, Pharmaceuticals